Beijing Tide Pharmaceutical Co. Ltd. has prepared proteolysis-targeting chimera (PROTAC) compounds comprising an ubiquitin ligase binding moiety bound to a protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting moiety through a linker.
Research at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. has led to the identification of sulfonylpiperazinyl compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) inhibitors and reported to be useful for the treatment of gram-negative bacterial infections.
Halia Therapeutics Inc. has reported the development of tyrosine-protein kinase receptor TYRO3 inhibitors potentially useful for the treatment of glioma.
Cullgen (Shanghai) Inc. has patented proteolysis targeting chimera (PROTAC) compounds comprising a DDB1 binding moiety covalently bonded to a target protein binding moiety through a linker. They are reported to be useful for the treatment of cancer.
Compounds reported to be useful for the treatment of myotonic 1, myotonic 2 and muscular dystrophy have been described in a City University of New York patent.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have jointly patented pyrimidine tricyclic derivative soluble guanylate cyclase (sGC) activators. They are reported to be useful for the treatment of heart failure and hypertension.
RSS